Sort by
Keyphrases
Colorectal Cancer
100%
Biological Agents
100%
Comparative Effectiveness
100%
Ethnic Minorities
100%
Median Overall Survival
40%
Chemotherapy
40%
Metastatic Colorectal Cancer (mCRC)
40%
Hispanic
40%
United States
20%
Overall Survival Rate
20%
Real-world Impact
20%
Aging
20%
Soaring
20%
Cytotoxic Chemotherapy
20%
Racial Groups
20%
Bevacizumab
20%
Statistical Significance
20%
Score-based
20%
Jacobi
20%
Practice Changing
20%
Panitumumab
20%
Cetuximab
20%
White People
20%
5-year Survival
20%
Bronx
20%
Overall Survival
20%
Healthcare Expenditure
20%
Young Adolescents
20%
Grant Proposal
20%
Age of Diagnosis
20%
People of Color
20%
Catering
20%
SEER-Medicare Database
20%
Older Adults
20%
Clinically Meaningful Improvement
20%
Critical Risk Factors
20%
Log-rank Test
20%
Propensity Score
20%
Cure Rate
20%
Ethnic Groups
20%
Medicine and Dentistry
Biological Product
100%
Colorectal Carcinoma
100%
Overall Survival
66%
Metastatic Colorectal Cancer
33%
Ethnic Group
16%
Cetuximab
16%
Panitumumab
16%
Health Care
16%
Bevacizumab
16%
Medicare
16%
Log Rank Test
16%
Racial Group
16%
Survival Rate
16%
Cytotoxic Chemotherapy
16%
Nursing and Health Professions
Biological Product
100%
Colorectal Carcinoma
100%
Overall Survival
66%
Metastatic Colorectal Cancer
33%
Bevacizumab
16%
Medicare
16%
Log Rank Test
16%
Propensity Score
16%
Ethnic Group
16%
Panitumumab
16%
Cetuximab
16%
Survival Rate
16%
Health Care Cost
16%
Racial Group
16%